Genome synthesis and editing
Traditional molecular cloning and gene editing workflow steps for manual DNA synthesis are tedious and can take weeks to complete. The BioXp™ system enables rapid synthesis within days to weeks, as well as the ability to modify large constructs and full-length genomes. It also enhances productivity during the design phase of genome editing workflows through the automated synthesis of gene fragments, clones, and variant libraries. Telesis Bio’s core technology was originally developed for pandemic preparedness applications, which enabled the team to pivot quickly to help researchers battle COVID-19. As a result, the team successfully created the first full-length SARS-CoV-2 synthetic genome de novo in April 2020 using the BioXp™ synthetic biology workstation. Jason Lehman, Product Marketing Manager at Telesis Bio spoke more about how synthetic genomes will continue to be very powerful research tools for fighting future epidemic health crises on the BCC Research podcast, “You Should Know This.” Listen to the full episode here.
Metabolic engineering involves reconstructing and optimizing biosynthetic pathways in model organisms, creating robust cellular factories designed to carry out a specific task. With the gene synthesis capabilities of our BioXp™ system, and the complex or high-fidelity assembly made possible with Gibson Assembly® technology, scientists can improve the speed and accuracy of metabolic engineering for even the most complex genetic circuitry. Cellibre, a next-gen cellular agriculture company partnered with Telesis Bio, to engineer a recombinant protein with 5X the activity of the wild-type sequence and reduce project timelines to weeks instead of months.
By leveraging targeted variant libraries from Telesis Bio that offer industry-leading fidelity and speed they were able to leverage an efficient approach to engineering high-efficiency enzymes in weeks instead of months.
Whether it’s for personalized cancer therapies built on neoantigens or biologics-based discovery of novel therapeutics, rapid DNA and mRNA synthesis are essential for the acceleration of precision medicine. The BioXp™ system’s on-demand, high-throughput synthesis, and flexible cloning into a variety of vectors allow for quick screening and development of personalized cancer treatments. Additionally, the system streamlines the generation of combinatorial libraries, variant gene fragments, and clones across all steps. This increases the quantity and quality of suitable biologics candidates to advance into additional downstream applications and reduces build cycle time by up to 80%.
The BioXp system’s high-throughput gene synthesis and flexible cloning modalities enable rapid screening and design of novel chimeric antigen receptors, engineered T cell receptors, and artificial transcription factors. For cancer patients with few other treatment options, the need for new targeted immunotherapies is genuinely a matter of life or death. So how to accelerate the development of new therapies? One key component is automated DNA synthesis. Watch this webinar featuring Stephen Schoenberger of the La Jolla Institute for Immunology, and Aaron Miller from Moores Cancer Center at UC San Diego Health share how they leveraged synthetic biology to accelerate precision therapy workflows.
"Thanks to the BioXp™ system, the time required to go from understanding and ordering a digital sequence to functional testing of a given TCR has gone from over three weeks to under three days — I am amazed and grateful."
Stephen Schoenberger, PhD
La Jolla Institute of Immunology